Oruka Therapeutics (NASDAQ:ORKA) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Oruka Therapeutics (NASDAQ:ORKA) from a hold rating to a sell rating in a research note published on Saturday morning.

A number of other research firms have also issued reports on ORKA. BTIG Research began coverage on Oruka Therapeutics in a report on Thursday, May 22nd. They set a “buy” rating on the stock. Wedbush reissued an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a report on Thursday, May 15th. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $40.38.

Oruka Therapeutics Stock Performance

Shares of ORKA stock opened at $12.43 on Friday. The stock’s 50-day moving average is $10.39 and its two-hundred day moving average is $12.96. The firm has a market cap of $465.39 million, a price-to-earnings ratio of -1.98 and a beta of -0.38. Oruka Therapeutics has a 1 year low of $5.49 and a 1 year high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.17. As a group, research analysts predict that Oruka Therapeutics will post -3.41 EPS for the current year.

Institutional Investors Weigh In On Oruka Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. FMR LLC boosted its holdings in Oruka Therapeutics by 17.7% in the 4th quarter. FMR LLC now owns 5,512,300 shares of the company’s stock valued at $106,883,000 after purchasing an additional 830,000 shares in the last quarter. Fairmount Funds Management LLC lifted its position in shares of Oruka Therapeutics by 5.0% during the 4th quarter. Fairmount Funds Management LLC now owns 3,371,922 shares of the company’s stock valued at $65,382,000 after acquiring an additional 160,000 shares during the period. VR Adviser LLC lifted its position in shares of Oruka Therapeutics by 6.5% during the 4th quarter. VR Adviser LLC now owns 3,285,620 shares of the company’s stock valued at $63,708,000 after acquiring an additional 200,000 shares during the period. RTW Investments LP lifted its position in shares of Oruka Therapeutics by 5.1% during the 4th quarter. RTW Investments LP now owns 1,945,649 shares of the company’s stock valued at $37,726,000 after acquiring an additional 95,001 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Oruka Therapeutics by 4,161.2% during the 4th quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company’s stock valued at $31,231,000 after acquiring an additional 1,572,853 shares during the period. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.